ArticlePloS one2025
Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON): A personalized randomized clinical trial protocol.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06336642 (Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-flow supplemental oxygen (LFSO), high-flow nasal cannula (HFNC), and non-invasive ventilation (NIV) are often used for palliation of dyspnea in hospitalized patients. However, it is unclear how patients prefer to use these modalities and how they can be personalized for optimal dyspnea relief. The objective of this randomized clinical trial is to compare the effect of a personalized respiratory therapist (RT)-led intervention, termed SPOT-ON, and enhanced usual care on dyspnea intensity in both hypoxemic and non-hypoxemic hospitalized patients with cancer.
methodsIn this two-arm, parallel group, partially blinded, waitlist-controlled randomized clinical trial, hospitalized patients with advanced cancer and at least moderate dyspnea intensity at rest (numeric rating scale [NRS] ≥4/10) will be randomized 1:1 to receive SPOT-ON immediately or after a 72-hour waiting period. The SPOT-ON intervention consists of a time-limited trial of LFSO, HFNC, and NIV for 10 minutes each, followed by personalized deployment of these modalities to tailor device settings and timing and duration of use based on patient preference over 72 hours. The waitlist control group will receive structured dyspnea education after enrollment and usual care. The primary outcome will be change in dyspnea NRS intensity from baseline to 24 hours. Secondary outcomes include dyspnea unpleasantness, vital signs, symptom burden, health-related quality of life, adverse events, pattern of device use, and hospital outcomes. We calculated that 150 patients (75 hypoxemic and 75 non-hypoxemic) will provide 80% power to detect a 1.2-point difference between groups with α = 0.025, assuming a standard deviation of 1.5 and 20% attrition. DISCUSSION: Successful completion of this clinical trial could inform the use of oxygen and supportive modalities to reduce dyspnea. This novel personalized clinical trial methodology involving time-limited trials to tailor therapy based on patient preferences may inform the design of future supportive care clinical trials.
trial registrationClinicaltrials.gov NCT06336642.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.